MedTrace Logo

Electromyography in Patients on Chronic Pyridostigmine Therapy

NCT02364180 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-05-09

Study results available
· View outcomes & findings →

Summary

We intend to measure evoked EMG at two sites in subjects who are chronically taking pyridostigmine.

Conditions

  • Muscle Weakness

Interventions

DIAGNOSTIC_TEST

Electromyography (EMG)

Sponsors & Collaborators

  • University of Toledo Health Science Campus

    lead OTHER

Principal Investigators

  • Shashi Bhatt, MD · The University of Toledo

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02364180 on ClinicalTrials.gov